Related Experiment Video

Updated: May 11, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is

Pierre Bigot1, Tarek Fardoun, Jean Christophe Bernhard

  • 1Cancerology Committee of the French Association of Urology (CCAFU), Paris, France, pibigot@chu-angers.fr.

World Journal of Urology
|April 30, 2013
PubMed
Abstract

Insights

Neoadjuvant targeted molecular therapies (TMTs) showed limited impact on reducing the size or level of inferior vena cava tumor thrombi in clear cell renal cell carcinoma patients. The study did not find significant improvements in surgical management due to these therapies.

Area of Science:

  • Oncology
  • Nephrology
  • Surgical Oncology

Background:

  • Inferior vena cava (IVC) tumor thrombi in clear cell renal cell carcinoma (ccRCC) pose significant management challenges.
  • Neoadjuvant targeted molecular therapies (TMTs) are increasingly explored to downstage tumors and improve surgical outcomes.

Purpose of the Study:

  • To evaluate the effect of neoadjuvant TMTs on the size and level of IVC tumor thrombi.
  • To assess the impact of neoadjuvant TMTs on the surgical management of ccRCC with IVC thrombi.

Main Methods:

  • Retrospective analysis of 14 ccRCC patients with IVC thrombi treated with neoadjuvant TMT.
  • Data collected included clinical, pathological, and perioperative information.
  • Tumor and thrombus size assessed by CT; thrombus level classified using Novick's criteria.

Main Results:

  • Before TMT, thrombus levels were predominantly Stage II (72%).
  • Post-TMT, 43% showed thrombus decrease, 43% no change, and 14% increase; only one patient (7%) experienced a downstage.
  • Primary tumor size showed a decrease in 50% of patients, but thrombus response was limited.

Conclusions:

  • Neoadjuvant TMT demonstrates limited efficacy in reducing the size or altering the level of IVC tumor thrombi in ccRCC.
  • The study did not find a significant benefit of neoadjuvant TMT in facilitating the surgical management of these complex cases.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.